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Abstract 
Objectives: To determine whether individual goal-oriented cognitive rehabilitation (CR) improves 
everyday functioning for people with mild-to-moderate dementia.  
Design and methods: Parallel group multi-centre single-blind randomised controlled trial (RCT) 
comparing CR added to usual treatment (CR) with usual treatment alone (TAU) for people with an 
ICD-10 diagnosis of Alzheimer’s, vascular or mixed dementia and mild-to-moderate cognitive 
impairment (MMSE score ≥ 18), and with a family member willing to contribute. Participants 
allocated to CR received ten weekly sessions over three months and four maintenance sessions over 
six months. Participants were followed up three and nine months post-randomisation by blinded 
researchers. The primary outcome was self-reported goal attainment at three months. Secondary 
outcomes at three and nine months included informant-reported goal attainment, quality of life, mood, 
self-efficacy, and cognition, and study partner stress and quality of life.  
Results: We randomised (1:1) 475 people with dementia; 445 (CR=281) were included in the 
intention to treat analysis at three months, and 426 (CR=208) at nine months. At three months there 
were statistically-significant large positive effects for participant-rated goal attainment (d=0.97, 95% 
CI 0.75 to 1.19), corroborated by informant ratings (d=1.11, 0.89 to 1.34). These effects were 
maintained at nine months for both participant (d=0.94, 0.71 to 1.17) and informant ratings (d=0.96, 
0.73 to 1.2). The observed gains related to goals directly targeted in the therapy. There were no 
significant differences in secondary outcomes. 
Conclusions: Cognitive rehabilitation enables people with early-stage dementia to improve their 
everyday functioning in relation to individual goals targeted in the therapy.  
Trial registration: Current Controlled Trials ISRCTN21027481 
Keywords 
Alzheimer’s disease, vascular dementia, activities of daily living, disability, goal-setting, non-
pharmacological intervention, person-centred, problem-solving, reablement 
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Key points 
  Cognitive rehabilitation (CR) is an individualized problem-solving therapy that aims to 
manage or reduce functional disability by addressing personal goals selected by people with 
dementia in an everyday context.   GREAT is the first large trial to show that CR improves participant and carer evaluations of 
everyday functioning in relation to specific, personally-meaningful goals targeted in therapy.  CR could be considered for inclusion in care pathways for people with mild to moderate 
dementia who require support to manage everyday life and to maintain engagement in 
activities and social participation.   
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Introduction 
Timely diagnosis provides an opportunity to equip people with dementia, and their family members, 
to manage the effects of the condition on everyday functioning and independence. Currently, 
however, access to non-pharmacological interventions is limited,1 and there is a particular need for 
practical, evidence-based interventions that directly support the ability to function in everyday life. 
People with dementia who have mild to moderate cognitive impairment typically have relatively 
preserved ability for procedural learning, and given appropriate support there is potential to change 
behaviour, implement new strategies, and learn or re-learn some important information2 in order to 
improve everyday functioning or maintain independence. Cognitive rehabilitation (CR), an 
intervention that addresses the impact of cognitive impairment on functional ability,3 has been adapted 
for people with dementia.4,5 CR is a person-centred, goal-oriented, problem-solving therapy aimed at 
managing or reducing functional disability, mitigating excess disability,6 and maximising engagement 
and social participation. 
In CR, people with dementia, and where possible their family members or other supporters, work 
collaboratively with a therapist to choose personally-relevant and meaningful goals relating to 
everyday activities.4,5 The therapist identifies the person’s intrinsic capacity and current level of 
functioning, assesses the requirements of the task or activity outlined in the goal, pinpoints areas 
where the two are mismatched and where problems arise, and helps devise a plan to overcome these 
problems using evidence-based rehabilitative methods. These methods may include use of 
environmental adaptations and prompts, introduction of compensatory strategies and memory aids, 
procedural learning of skills, and methods for learning or re-learning relevant information. The 
personal rehabilitation plan is put into practice over several sessions, which are conducted in the home 
setting to ensure that changes are directly implemented in everyday situations. Progress towards 
attaining the identified goals is evaluated through participant- and informant-reported levels of goal 
attainment.3  
Early studies consistent with this approach demonstrated benefits for people with dementia.7,8 These 
were confirmed in a series of feasibility studies9,10 and reports from other groups,11,12 followed by a 
pilot randomised controlled trial (RCT) that demonstrated superiority over an active control 
condition.13 The GREAT trial was designed to provide definitive evidence about clinical 
effectiveness. 
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Materials and Methods 
Design 
This was a multi-centre, single-blind pragmatic randomised controlled trial comparing CR added to 
usual treatment (CR) with usual treatment alone (TAU). Outcomes were assessed three and nine 
months post-randomisation. The trial was conducted in eight centres in England and Wales. Ethical 
approval was given by the Wales REC 5 National Health Service (NHS) research ethics committee 
(Reference 12/WA/0185). Participants and study partners provided written informed consent. The trial 
protocol was published14 and the trial was registered with Current Controlled Trials, reference 
ISRCTN21027481.  
Participants  
Participants were people of any age with an ICD-10 diagnosis of Alzheimer’s, vascular or mixed 
dementia and mild to moderate cognitive impairment as indicated by an MMSE15 score of 18 or 
above. If taking dementia-specific medication they had to have been receiving a stable dose for at 
least one month, with no expectation of change during the trial. They had to be able to give informed 
consent for participation, and to have a family member or other supporter (‘study partner’) willing to 
contribute. Exclusion criteria were a prior history of stroke, brain injury or other significant 
neurological disorder and, for practical reasons, inability to communicate in English. Any cases of 
uncertain eligibility were adjudicated by a panel of four clinicians.  
Sample size  
Power calculations were based on the pilot trial.13 To achieve 80% power to detect a medium effect size 
of 0.3, with alpha 0.05, in primary and secondary outcomes, for a two-sample comparison of means, we 
needed 175 people with dementia, together with their study partners, to complete the trial in each arm. 
Allowing for estimated potential attrition of 27%, we needed to randomise 480 people with dementia.  
Participant recruitment  
Participants were recruited through NHS services, support groups and Join Dementia Research. 
Recruitment was conducted by Clinical Research Network staff from 1st April 2013 to 31st March 
2016.  
 
Randomisation and masking 
Participants were individually randomised following consent and baseline assessment through secure 
web access to the remote randomisation centre. Randomisation was conducted by dynamic 
allocation16 to protect against subversion while maintaining good balance to the 1:1 allocation ratio. 
Participants were stratified by centre, gender, age (under 75 vs. 75 and above), and MMSE score 
(under 24 vs. 24 and above). To maintain blinding of the trial researchers who conducted follow-up 
  
This article is protected by copyright. All rights reserved. 
assessments, outcomes of randomisation were notified to the trial therapists only, and the trial 
therapists scheduled all follow-up visits by the researchers, irrespective of participants’ allocation. To 
assess the effectiveness of blinding, at follow-up the trial researchers indicated to which group they 
believed the participant was allocated.  
 
Intervention 
The intervention consisted of ten weekly one-hour individual sessions of goal-oriented CR over a 
three-month period followed by four one-hour maintenance sessions over the subsequent six months, 
conducted in the participant’s home. CR involved working collaboratively on up to three 
rehabilitation goals chosen by the participant using a problem-solving approach. This was 
supplemented as needed by addressing motivational and emotional difficulties through applying 
emotion regulation and behavioural activation strategies, reviewing and optimising participants’ 
existing use of strategies to manage cognitive disability, providing practice in maintaining attention 
and concentration, signposting to relevant services, and offering support for study partners. CR could 
potentially be delivered by therapists from various professional backgrounds; in this trial the 
therapists were nine occupational therapists and one nurse. Therapists attended a two-day initial 
training course and annual one-day refresher training sessions, and received regular centralised 
supervision to ensure fidelity to protocol and consistency across sites. Therapists completed therapy 
logs which were reviewed by the supervisor.  
Comparator 
The comparator was treatment as usual, typically consisting of medication, monitoring and general 
psychosocial support.  
Outcomes 
All assessments were conducted in participants’ homes by trained researchers blind to group 
allocation.  
The primary outcome was participant-rated goal attainment at three months, recorded using a 
previously-validated client-centred attainment measure, a simple 0 – 10 scale that is accessible and 
feasible for people with cognitive impairment to complete; an improvement of 2 points in the goal 
attainment rating for any individual goal is considered to be clinically significant.17-22 Participants’ 
individual goals were collaboratively identified through a semi-structured interview, the Bangor Goal-
Setting Interview, BGSI.23 All participants chose up to three goals at baseline and rated current 
attainment; attainment ratings were then averaged across each participant’s goals to give a single 
summary rating. These ratings were repeated at the three month follow-up, providing the primary 
outcome. Participants also rated goal attainment at nine months, study partners independently rated 
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participant goal attainment at three and nine months, and participants rated their satisfaction with their 
goal attainment at three and nine months.  
 
Other secondary outcomes for participants with dementia at three and nine months were self-reported 
self-efficacy (Generalised Self-Efficacy Scale),24 mood (Hospital Anxiety and Depression Scale),25 
and dementia-specific health-related quality of life (DEMQOL).26 Participants also completed a brief 
cognitive test battery covering memory (story recall from the Rivermead Behavioural Memory 
Test),27 attention (elevator counting and elevator counting with distraction subtests from the Test of 
Everyday Attention),28 and executive function (verbal letter fluency from the Delis-Kaplan Executive 
Function System).29 
Secondary outcomes for study partners at three and nine months were self-reported stress (Relatives’ 
Stress Scale),30 quality of life (WHOQOL-BREF),31 and health-related quality of life (EQ5D).32 
Analysis  
Analyses were conducted in IBM SPSS v.22 and R v.3.3.1. The main statistical analysis, conducted 
blind, was an intention to treat analysis. Missing data were addressed through multiple imputation of 
missing values using a predictive mean matching algorithm.33 Missing outcome measure scores at 
baseline were imputed using centre-level factors and the participant’s gender, age and baseline 
MMSE scores. Missing outcome measure scores at the three- and nine-month assessments were 
estimated based on centre-level factors, baseline characteristics and scores for the same outcome at 
the earlier time-point(s). In line with simulation-based observations of the D2 statistic’s performance 
for pooling p values,34 25 sets of imputations were generated using the method described above. For 
both primary and secondary outcomes, the analysis was a mixed-effect analysis of covariance 
(ANCOVA) adjusted for baseline score, allocation group and the stratification variables (age group, 
gender, MMSE score and centre). Baseline score, allocation group, age group, gender and MMSE 
score were treated as fixed effects, and centre as a random effect. Between-group effect sizes with 
confidence intervals (CIs) were calculated using Cohen’s d (the mean difference between the two 
arms, divided by the pooled standard deviation). For the primary outcome measure, pre-specified 
regression modelling was undertaken to identify potential effect-modifying factors, selected on 
clinical and theoretical grounds. Pre-specified exploratory analyses, not adjusted for multiple 
comparisons, examined the impact of the number of sessions received on primary and secondary 
outcomes at three and nine month follow up and investigated whether participants’ baseline ratings of 
goal importance and readiness to change were associated with outcomes.  
Sensitivity analyses compared the outcomes of analyses that included both imputed and complete case 
data with the outcomes of analyses that included complete cases only. An analysis based on treatment 
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received irrespective of group allocation was planned, but proved unnecessary as group allocation and 
treatment received were 100% consistent. 
Interviews were conducted with a consecutive series of participants and study partners completing the 
intervention in three of the trial sites by an interviewer independent of the trial. Interviews followed a 
semi-structured schedule in which participants and study partners were asked about their experiences 
and perceptions of the intervention, its usefulness, the degree of effort required, and any impact on 
day-to-day life. Data were analysed thematically from a critical realist perspective, taking an inductive 
approach to identifying and exploring patterns of meaning. Initial coding of the first five transcripts 
was undertaken by two researchers working independently. The resulting lists of themes were 
compared and discussed until consensus was reached about content and organisation, after which each 
researcher re-coded the transcripts. Related themes were clustered together and the clusters ordered 
into group-level themes and sub-themes, and integrated into an overall thematic map by both 
researchers working together. The remaining transcripts were then coded by a single researcher. 
Findings are presented only briefly here but will be reported more fully in a separate paper. 
Patient and public involvement 
Alzheimer’s Society Research Network volunteers contributed to development of the trial protocol 
and served as experts by experience on the Trial Steering Committee (TSC). 
Changes to protocol 
The trial was initially set up with six sites, but two further sites were added to ensure recruitment 
targets were met. Interviews with a sub-set of participants and study partners were added on the 
recommendation of the experts by experience.  
 
Results 
The flow of participants through the trial is shown in Figure 1.  Following baseline assessment, 475 
participants were randomised to either CR (n=239) or TAU (n=236). One participant who did not 
meet diagnostic criteria was incorrectly randomised and was withdrawn from analysis. All 
participants received their allocated condition, and 90% of CR participants completed at least ten 
sessions. Six participants in the CR group withdrew from the intervention after at least two sessions 
but remained in the trial to complete follow-up assessments. Retention in the trial was 94% at three 
months and 90% at nine months. Of 36 couples invited to participate in an interview following the 
nine-month follow-up, 26 agreed, although in one case only the study partner completed the 
interview.  
(((Figure 1 near here))) 
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Sample characteristics 
Demographic and clinical characteristics of the participants with dementia and study partners are 
summarised in Table 1. There were 111 serious adverse events reported during the trial, affecting 68 
participants and 26 study partners and mostly involving hospitalisation; blinded assessors judged that 
none were related to trial participation.  
 
(((Table 1 near here))) 
 
 
Numbers analysed 
The intention to treat analysis included data from 474 participants at baseline (CR n=238; TAU 
n=236), 445 participants at three months (CR n=218; TAU n=227) and 426 participants at nine 
months (CR n=208; TAU n=218).  
Main outcome analyses 
The primary outcome was participants’ goal attainment ratings on the BGSI at three months. 
Participant attainment and satisfaction ratings and study partner attainment ratings across all time 
points, and details of the statistical analyses, are summarised in Table 2. According to these 
participant-reported outcomes, CR was effective in improving functioning in the targeted areas at 
three months from the perspective of both participants and study partners, and this improvement was 
maintained at nine months. Note that the analyses reported in Table 2 cover all goals that were 
identified at baseline, and for the CR group this included a number of goals that were not addressed in 
the intervention. The CR group participants identified 679 goals and worked on 481 (71%) of these 
with the therapists. Taking just the 481 goals that were addressed in therapy, the mean change in 
participants’ goal attainment ratings was an improvement of 2.84 points (s.d. 2.84) at three months 
and 2.77 points (s.d. 3.18) at nine months, while study partners’ ratings showed an improvement of 
3.09 points (s.d. 2.73) at three months and 2.76 points (s.d. 3.14) at nine months.  
(((Table 2 near here))) 
 
For the primary outcome measure at three months, linear mixed-effects models examining participant 
(centre, MMSE score, diagnosis, medication use, education, socio-economic status, and blinding 
effectiveness) and study partner (centre, gender, age, education, hours spent helping the participant, 
type of relationship with the participant) factors predicting change in participants’ goal attainment 
ratings from baseline to follow-up in the CR group were not statistically significant apart from socio-
economic status, where higher socio-economic status was associated with better outcomes; see 
Supplementary Table 1. Participants’ baseline ratings of the importance of each goal did not predict 
improvement. Ratings of readiness to change in relation to the goal were significantly associated with 
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improvement in attainment ratings (t(403)=2.66,  r=0.13,  p=0.008), as was adherence, defined as 
number of CR sessions completed (b=0.17, SE=0.09, t(215)=2.01, p=0.046, 95% CI 0 to 0.34).  
 
Scores on secondary outcome measures at all time-points, and ANCOVA analyses, are presented in 
Table 3. Following Bonferroni correction there were no significant differences. Effect sizes were 
small to negligible, although in some cases with wide confidence intervals.  
(((Table 3 near here))) 
Sensitivity analyses 
Results from the analysis of complete case data were very similar to those of the multiple imputation 
analysis and did not alter the pattern of findings; see Supplementary Tables 2 and 3. The difference in 
attrition between CR and TAU was minimal and no statistically significant differences were observed 
in baseline characteristics or in primary and secondary outcomes for participants who withdrew and 
remained in the study; see Supplementary Tables 4 and 5. Consequently multiple imputation did not 
need to be modified.  
 
Qualitative evaluation 
Participants and study partners who were interviewed after completing the trial responded positively 
to the intervention, although for some study partners this was tempered by the knowledge that 
dementia would continue to progress. Participants and study partners valued the relationship with the 
therapist, both for the specific focus on developing and personalising strategies and for the more 
general information and support provided. Interviewees said that the therapy had been effective in 
supporting engagement in everyday activities, and had improved their adjustment to living with 
dementia, resulting in less anxiety, better coping skills, feelings of empowerment, and improved well-
being and quality of life. Some commented that the intervention increased their problem-solving 
ability and enabled them to develop new strategies for different situations. 
Discussion 
The GREAT trial demonstrates that individualised, goal-oriented cognitive rehabilitation (CR) is an 
effective intervention for people with early-stage Alzheimer’s disease, vascular or mixed dementia 
wishing to improve aspects of their everyday functioning. Outcomes elicited from participants and study 
partners indicated that CR improved functioning in the areas targeted in the therapy at three months, and 
this improvement was maintained at nine months. When considering the goals actually addressed in 
therapy, improvements met criteria for clinical significance. High levels of adherence and low attrition 
indicated that the intervention was acceptable to participants and study partners. Participants and study 
partners interviewed in depth viewed the intervention positively and felt that it was beneficial.  
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Strengths and limitations  
A key strength is that the intervention targeted real-life situations and aimed to improve participants’ 
functioning in areas that were meaningful to them, avoiding any problems relating to lack of transfer 
or generalisation of effects. The primary outcome was a proximal measure, directly evaluating 
perceptions of change in the areas targeted in the intervention. No trial-related adverse events or 
harms were identified. 
There are several limitations to consider. Due to the constraints of trial design, the goal-setting 
interview was conducted by researchers not involved in delivering therapy, whereas in clinical 
practice the goal-setting process would be undertaken by the therapist and might be more efficient. 
While participants were invited to select up to three goals, on average the therapists were able to 
address two goals per participant. The primary outcome was based on ratings of progress with all 
goals identified at baseline, rather than just those goals that were actually addressed; therefore, the 
overall estimate of improvement in goal attainment is a conservative one. Ratings for the goals that 
were directly addressed showed a clinically-meaningful degree of change. The trial design did not 
allow us to conclusively demonstrate that benefits were due to the specific effects of CR rather than 
non-specific effects of contact with a therapist; however, the observed gains related specifically to 
improvements in functional ability for goals directly targeted in the therapy, and in the pilot trial, CR 
demonstrated benefits over an active control condition. In selecting secondary outcome measures, it 
would have been useful to include a measure of functional ability.  
 
How the findings relate to other evidence 
The results confirm the finding from our pilot trial13 that CR is effective in improving those aspects of 
everyday functioning targeted in the intervention. A different, but related, approach to improving 
everyday functioning involves structured training in completing selected activities of daily living. 
Two recent trials35,36 found that performance on trained tasks improved, although there was no 
evidence of generalisation to everyday situations35 or improvement in secondary outcomes such as 
quality of life. The only other large-scale trial of CR37 reported that, compared to usual treatment, CR 
participants showed less functional decline at 24 months, a six-month delay in institutionalisation and 
lower overall rates of institutionalisation, but no significant differences mood or quality of life. The 
CR intervention in this trial was poorly-described and goal attainment was not directly measured. 
These findings taken together indicate that it is possible to promote improved functional ability 
through both CR and structured training. In CR, this improvement directly benefits targeted areas of 
everyday life, whereas the improvements observed following structured task-specific training may not 
generalise to real-life situations. Other benefits resulting from CR or structured training are not 
captured by available standardised outcome measures. In GREAT, there are several possible 
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explanations for the lack of change in secondary outcomes. The finding of no differences in cognitive 
test scores was unsurprising as the intervention does not directly seek to improve cognitive function. 
As only a small proportion of participants reported clinical levels of depression or anxiety at baseline, 
there was little scope for the intervention to demonstrate improvements in these domains. The absence 
of reduction in stress for study partners might be explained by the fact that the intervention did require 
effort from them, both to engage when they may feel they have already tried various strategies 
without success, and secondly to support the implementation of strategies through the therapy. 
However, the qualitative findings were at odds with the results from secondary outcome measures. 
The intervention may therefore have provided wider benefits that were not detected by available 
standardised measures.  
 
Implications  
The study shows that people with dementia are able to identify key goals, and are motivated to 
address them. Readiness to make changes in these areas predicts outcome and is an important factor 
for practitioners to consider at initial assessment. However, only those provided with structured 
support are able to make demonstrable progress in attaining their goals. Engagement in this process is 
crucial for progress to be made, and is facilitated through the positive relationship with the 
practitioner and the encouragement and support the practitioner provides. The findings demonstrate 
the potential of practical interventions to enable people with dementia to function better in areas that 
are important to them and that can make a difference to their lives. While GREAT followed a 
structured protocol, CR is not a fixed intervention, and can be adapted to different contexts to meet a 
variety of needs.5 If CR can be delivered in real-world practice in a cost-effective manner, it could 
form a component of post-diagnostic care pathways for those recently diagnosed who would welcome 
support to develop strategies for living with dementia, or of community reablement or home care 
packages for those with more complex needs.  
Conclusions 
Individual, goal-oriented CR enables people with dementia to function better and more independently in 
relation to goals targeted in the therapy. This personalised approach addresses individual concerns in the 
home setting and can be applied flexibly to meet different kinds of need. Enablement is an appropriate 
objective for services that support people with dementia, and the application of CR provides a means of 
translating this objective into practical support in a way that is acceptable and relevant to people with 
dementia and their families. CR can potentially contribute to improving the choice of interventions 
available to people living with dementia who have mild to moderate cognitive impairment, helping to 
address the current gap in provision of psychosocial interventions.1 
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Table 1. Demographic and clinical characteristics of the participants and study partners 
 
(a) Participants with dementia  
Measure Whole sample 
n=474 
CR 
n=238 
TAU 
n=236 
Age, mean (SD), range 78.56 (7.07); 53 to 95 78.25 (7.13); 53 to 95 78.87 (7.01); 55 to 95 
Sex (male), n (%) 248 (52.3) 124 (52.1) 124 (52.5) 
Ethnicity, n (%):    
White 457 (96.4) 226 (95.0) 231 (97.9) 
Mixed / Multiple ethnic 
group 
2 (0.4) 2 (0.8) 0 (0) 
Asian / Asian British 6 (1.2) 3 (1.3) 3 (1.3) 
Black / African / Caribbean / 
Black British 
7 (1.5) 5 (2.1) 2 (0.9) 
Other ethnic group 2 (0.4) 2 (0.8) 0 (0) 
First language (English), n 
(%) 
445 (93.9) 222 (93.3) 223 (94.5) 
Marital status (married), n 
(%) 
330 (69.6) 
n=474 
167 (70.2) 
n=238 
163 (69.1) 
n=236 
Years of education 12.57 (3.37); 5 to 33 
n=471 
12.57 (3.33); 6 to 24 
n=236 
12.58 (3.42); 5 to 33 
n=235 
Occupational status, n (%):     
I Professional 52 (11.0) 23 (9.7) 29 (12.3) 
II Managerial/technical 157 (33.1) 81 (34.0) 76 (32.2) 
III N Skilled, non-manual 103 (21.7) 54 (22.7) 49 (20.8) 
III M Skilled, manual 80 (16.9) 41 (17.2) 39 (16.5) 
IV Partly skilled 50 (10.5) 24 (10.1) 26 (11.0) 
V Unskilled 32 (6.8) 15 (6.3) 17 (7.2) 
Diagnosis, n (%):    
Alzheimer’s disease 284 (59.9) 139 (58.4) 145 (61.4) 
Vascular dementia 74 (15.6) 43 (18.1) 31 (13.1) 
Mixed 116 (24.5) 56 (23.5) 60 (25.4) 
MMSE 23.82 (3.02); 18 to 30 23.89 (3.04); 18 to 30 23.75 (3.02); 18 to 30 
Charlson Co-Morbidity 
Index weighted score, mean 
(SD), range 
2.52 (1.47); 1 to 11 2.49 (1.47); 1 to 11 2.55 (1.48); 1 to 10 
Subjective rating of health, n 
(%): 
   
Excellent 39 (8.2) 20 (8.4) 19 (8.1) 
Very good 125 (26.4) 65 (27.3) 60 (25.4) 
Good 159 (33.5) 77 (32.4) 82 (34.7) 
Fair 121 (25.5) 61 (25.6) 60 (25.4) 
Poor 30 (6.3) 15 (6.3) 15 (6.4) 
DEMQoL, mean (SD), range 92.30 (12.33); 39 to 
112; n=472 
92.00 (12.90); 39 to 
112; n=237 
92.61 (11.75); 39 to 
112; n=235 
GSES, mean (SD), range 30.94 (5.09); 11 to 40; 
n=469 
30.75 (4.81); 13 to 40; 
n=237 
31.13 (5.35); 11 to 40; 
n=232 
HADS, mean (SD), range: n=472 n=238 n=234 
Depression 3.77 (2.79); 0 to 14 3.87 (2.83); 0 to 12 3.67 (2.75); 0 to 14 
Anxiety 5.14 (3.64); 0 to 16 5.29 (3.67); 0 to 16 4.98 (3.62); 0 to 16 
RBMT, mean (SD), range: n=473 n=237 n=236 
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Immediate recall 2.66 (2.11); 0 to 11.5 2.58 (2.10); 0 to 9.5 2.73 (2.12); 0 to 11.5 
Delayed recall 0.38 (1.96); -1 to 9 0.39 (1.94); -1 to 8 0.37 (1.97); -1 to 9 
TEA, mean (SD), range:    
Elevator counting 6.39 (1.16); 0 to 7 
n=463 
6.35 (1.27); 0 to 7 
n=232 
6.42 (1.05); 1 to 7 
n=231 
 
Elevator counting with 
distraction 
4.55 (2.72); 0 to 9; 
n=448 
4.39 (2.68); 
0 to 9; n=223 
4.72 (2.75); 
0 to 9; n=225 
DKEFS verbal fluency, mean 
(SD), range 
26.27 (11.82); 2 to 64; 
n=470 
25.78 (11.61); 2 to 64; 
n=235 
26.77 (12.03); 3 to 58; 
n=235 
Medication use 
n, % reporting use of: 
n=438 n=215 n=223 
Dementia medications  332 (75.8) 157 (73.0) 175 (78.5) 
Hypnotics and anxiolytics  3 (0.7) 1 (0.5) 2 (0.9) 
Anti-psychotic medication 6 (1.4) 2 (0.9) 4 (1.8) 
Antidepressants  98 (22.4) 57 (26.5) 41 (18.4) 
Anti-epileptics  2 (0.5) 1 (0.5) 1 (0.5) 
Data are mean (s.d.) range, or n (%). CR Cognitive rehabilitation, TAU Treatment as usual, MMSE 
Mini–Mental State Examination (higher scores indicate better performance), DEMQOL People with 
DEMentia Quality Of Life questionnaire (higher scores indicate better quality of life), GSES 
Generalized Self-Efficacy Scale (higher scores indicate stronger sense of perceived self-efficacy), 
HADS Hospital Anxiety and Depression Scale (higher scores indicate higher levels of anxiety and 
depression), RBMT Rivermead Behavioural Memory Test (higher scores indicate better 
performance), TEA Test of Everyday Attention (higher scores indicate better performance), D-KEFS 
Delis-Kaplan Executive Function System (higher scores indicate better performance) 
 
(b) Study partners 
Measure Whole sample  
n=474 
CR 
n=238 
TAU 
n=236 
Relationship to participant  
with dementia, n (%): 
   
Spouse/partner 331 (69.8) 167 (70.2) 164 (69.5) 
Adult child (including in-
law) 
118 (24.9) 58 (24.3) 60 (25.4) 
Other 25 (5.3) 13 (5.5) 12 (5.1) 
Age, mean (SD), range 68.74 (13.01); 17 to 92 68.45 (13.76); 17 to 92 69.04 (12.24); 23 to 92 
Sex (male), n (%) 142 (30.0) 75 (31.5) 67 (28.4) 
Ethnicity, n (%):    
White 449 (94.7) 224 (94.1) 225 (95.3) 
Mixed / Multiple ethnic 
group 
5 (1.1) 4 (1.7) 1 (0.4) 
Asian / Asian British 10 (2.1) 4 (1.7) 6 (2.5) 
Black / African / Caribbean / 
Black British 
8 (1.7) 6 (2.5) 2 (0.8) 
Other ethnic group 2 (0.42) 0 (0) 2 (0.9) 
First language (English), n 
(%) 
443 (93.5) 222 (93.3) 221 (93.6) 
Marital status (married), n 
(%) 
393 (82.9) 187 (78.6) 206 (87.3) 
Years of education, mean 
(SD), range 
13.49 (3.52); 4 to 26;  
n=472 
13.67 (3.45); 5 to 25;  
n=237 
13.32 (3.58); 4 to 26;  
n=235 
Occupational status, n (%):    
I Professional 49 (10.3) 30 (12.6) 19 (8.1) 
II Managerial/technical 158 (33.3) 74 (31.1) 84 (35.6) 
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Data are mean (s.d.) range, or n (%). CR Cognitive rehabilitation, TAU Treatment as usual, RSS 
Relatives’ Stress Scale (higher scores indicate higher levels of caregiving-specific stress), WHOQOL-
BREF World Health Organisation Quality of Life Instrument – brief version (higher scores indicate 
better quality of life), EQ5D3L European Quality of Life 5 Dimensions questionnaire Level version 
(higher score indicates higher health status), VAS Visual Analogue Scale (higher score indicates 
higher health status) 
  
III N Skilled, non-manual 137 (28.9) 64 (26.9) 73 (30.9) 
III M Skilled, manual 47 (9.9) 24 (10.1) 23 (9.7) 
IV Partly skilled 55 (11.6) 27 (11.3) 28 (11.9) 
V Unskilled 20 (4.2) 14 (5.9) 6 (2.5) 
NA 8 (1.7) 5 (2.1) 3 (1.3) 
Stress (RSS), mean (SD), 
range 
n=471; 18.96 (9.44);  
0 to 52 
n=236; 18.85 (9.04);  
2 to 46  
n=235; 19.08 (9.83);  
0 to 52 
WHOQOL domains, mean 
(SD), range: 
   
Physical n=470; 15.34 (2.95);  
5 to 20 
n=237; 15.30 (3.00);  
5 to 20 
n=233; 15.37 (2.90);  
7 to 20 
Psychological n=470; 15.14 (2.15);  
8 to 20 
n=237; 15.13 (2.19);  
8 to 20 
n=233; 15.15 (2.10);  
8 to 20 
Social n=468; 15.13 (2.66);  
5 to 20 
n=235; 15.19 (2.67);  
5 to 20 
n=233; 15.07 (2.66);  
7 to 20 
Environmental n=470; 16.43 (2.15);          
10 to 20 
n=237; 16.35 (2.30);  
10 to 20 
n=233; 16.52 (1.99); 
10 to 20 
EQ5D3L, mean (SD), range:    
Index n=468; 0.78 (0.25);  
-0.18 to 1 
n=235; 0.77 (0.25);      
-0.18 to 1 
n=233; 0.79 (0.24); 
-0.07 to 1 
VAS n=467; 74.48 (19.95);  
0 to 100 
n=234; 73.52 (20.95); 
1 to 100 
n=233; 75.44 (18.90); 
0 to 100 
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Table 2. Goal attainment ratings at baseline, three-month and nine-month follow-up, and statistical 
comparisons 
 
(a) Goal attainment ratings  
 
Measure CR   TAU   
 Baseline 
(n=238) 
3 months 
(n=218) 
9 months 
(n=205) 
Baseline 
(n=236) 
3 months 
(n=227) 
9 months 
(n=211) 
Participant rating of 
attainment 
3.53 
(1.74) 
6.10 
(1.99) 
6.05 
(2.21) 
3.55 
(1.59) 
4.41 
(1.84) 
4.22 
(2.00) 
Participant rating of 
satisfaction 
3.76 
(1.76) 
6.47 
(1.88) 
6.75 
(1.97) 
3.86 
(1.49) 
5.05 
(1.94) 
5.26 
(2.05) 
Study partner rating 
of attainment 
2.76 
(1.43) 
5.46 
(1.94) 
5.21 
(2.33) 
2.72 
(1.32) 
3.55 
(1.73) 
3.31 
(1.96) 
Data are mean (s.d.). CR Cognitive rehabilitation, TAU Treatment as usual 
 
(b) Statistical comparison at three-month follow-up. ANCOVA adjusted for baseline score, 
allocation group and stratification variables, age, gender, MMSE score and site 
 
Measure p Bonferroni 
adjusted p1 
Mean 
difference 
95% CI for 
mean 
difference 
d 95% CI 
for d 
Participant rating of 
attainment <0.001 NA 1.58 1.27 to 1.90 0.81 0.62 to 1 
Participant rating of 
satisfaction <0.001 <0.001 1.34 1.01 to 1.66 0.7 
0.51 to 
0.88 
Study partner rating 
of attainment <0.001 <0.001 1.75 1.42 to 2.07 0.93 
0.74 to 
1.12 
1
 19 adjustments in total to adjust for all the participant and carer outcome measure comparisons, 
except for the primary outcome. 
CI Confidence intervals. NA: Not applicable, as no correction was planned for the primary outcome. 
The d effect size estimates were based on a fixed effect size model as they cannot be derived directly 
from the mixed effects model, and were calculated by converting eta squared to r, and then converting 
r to d. 
 
 
(c) Statistical comparison at nine-month follow-up. ANCOVA adjusted for baseline score, 
allocation group and stratification variables, age, gender, MMSE score and site 
 
Measure p Bonferroni 
adjusted p2 
Mean 
difference 
95% CI for 
mean 
difference 
d 95% CI 
for d 
Participant rating of 
attainment <0.001 <0.001 1.71 1.35 to 2.08 0.8 
0.61 to 
0.99 
Participant rating of 
satisfaction <0.001 <0.001 1.36 1 to 1.73 0.67 
0.49 to 
0.86 
Study partner rating 
of attainment <0.001 <0.001 1.70 1.32 to 2.09 0.79 
0.60 to 
0.97 
2
 20 adjustments in total to adjust for all the participant and carer outcome measure comparisons. 
CI Confidence intervals. The d effect size estimates were based on a fixed effect size model as they 
cannot be derived directly from the mixed effects model, and were calculated by converting eta 
squared to r, and then converting r to d. 
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Table 3. Scores on secondary outcome measures at baseline, three-month and nine-month follow-up, 
and statistical comparisons 
 
(a) Scores for participants with dementia 
Measure CR  TAU 
 Baseline 3 months 9 months Baseline 3 months 9 months 
DEMQoL 
 
n=237 
92.00  
(12.90) 
39 to 112 
n=218 
92.79 
(11.95) 
51 to 112 
n=204 
92.36 
(12.00) 
54 to 112 
n=235 
92.61 
(11.75) 
47 to 111 
n=227 
93.20 
(12.00) 
51 to 111 
n=213 
92.25 
(12.82) 
45 to 112 
GSES 
 
n=237 
30.75 
(4.81) 
13 to 40 
n=215 
30.98 
(4.62) 
18 to 40 
n=194 
30.76 
(4.91) 
15 to 40 
n=232 
31.13 
(5.35) 
11 to 40 
n=224 
30.59 
(5.61) 
11 to 40 
n=207 
30.62 
(5.60) 
10 to 40 
HADS depression 
 
n=238 
3.87 
(2.83) 
0 to 12 
n=218 
3.90 
(2.86) 
0 to 15 
n=194 
4.19 
(3.23) 
0 to 17 
n=234 
3.67 
(2.75) 
0 to 14 
n=226 
3.74 
(2.69) 
0 to 12 
n=210 
3.83 
(2.82) 
0 to 17 
HADS anxiety 
 
n=238 
5.29 
(3.67) 
0 to 16 
n=216 
5.13 
(3.66) 
0 to 17 
n=193 
5.63 
(3.83) 
0 to 18 
n=234 
4.98 
(3.62) 
0 to 16 
n=226 
4.61 
(3.41) 
0 to 15 
n=210 
4.88 
(3.37) 
0 to 20 
RBMT immediate 
recall 
n=237 
2.58  
(2.10) 
0 to 9.50 
n=218 
2.88 
(2.16) 
0 to 10 
n=200 
2.34 
(2.09) 
0 to 10 
n=236 
2.73 
(2.12) 
0 to 11.50 
n=226 
2.79 
(2.12) 
0 to 11 
n=211 
2.37 
(1.96) 
0 to 10 
RBMT delayed recall 
 
n=237 
0.39 
(1.94) 
-1 to 8 
n=217 
0.94 
(2.31) 
-1 to 8.50 
n=200 
0.23 
(1.97) 
-1 to 8.50 
n=236 
0.37 
(1.97) 
-1 to 9 
n=225 
0.66 
(2.16) 
-1 to 11 
n=210 
0.36 
(1.97) 
-1 to 9.50 
TEA elevator 
counting 
n=232 
6.35 
(1.27) 
0 to 7 
n=210 
6.31 
(1.23) 
0 to 7 
n=191 
6.21 
(1.41) 
0 to 7 
n=231 
6.42 
(1.05) 
1 to 7 
n=219 
6.36 
(1.22) 
0 to 7 
n=206 
6.24 
(1.32) 
1 to 7 
TEA elevator 
counting with 
distraction 
n=223 
4.39 
(2.68) 
0 to 9 
n=198 
4.62 
(3.08) 
0 to 10 
n=177 
4.66 
(3.11) 
0 to 10 
n=225 
4.72 
(2.75) 
0 to 9 
n=208 
4.90 
(3.15) 
0 to 10 
n=193 
4.52 
(3.07) 
0 to 10 
DKEFS verbal 
fluency 
 
n=235 
25.78 
(11.61) 
2 to 64 
n=217 
26.29 
(12.56) 
0 to 58 
n=198 
26.30 
(13.32) 
0 to 62 
n=235 
26.77 
(12.03) 
3 to 58 
n=227 
26.80 
(12.38) 
3 to 68 
n=211 
25.90 
(12.36) 
1 to 67 
Data are mean (s.d.) range. CR Cognitive rehabilitation, TAU Treatment as usual, DEMQOL People 
with DEMentia Quality Of Life questionnaire (higher scores indicate better quality of life), GSES 
Generalized Self-Efficacy Scale (higher scores indicate stronger sense of perceived self-efficacy), 
HADS Hospital Anxiety and Depression Scale (higher scores indicate higher levels of anxiety and 
depression), RBMT Rivermead Behavioural Memory Test (higher scores indicate better 
performance), TEA Test of Everyday Attention (higher scores indicate better performance), D-KEFS 
Delis-Kaplan Executive Function System (higher scores indicate better performance). 
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(b) Scores for study partners 
Measure CR  TAU 
 Baseline 3 months 9 months Baseline 3 months 9 months 
RSS 
 
n=236 
18.85 
(9.04) 
2 to 46 
n=212 
19.42 
(9.62) 
2 to 46 
n=200 
21.23 
(9.92) 
2 to 51 
n=235 
19.08 
(9.83) 
0 to 52 
n=221 
20.42 
(10.33) 
1 to 54 
n=211 
21.65 
(10.74) 
2 to 50 
WHOQOL physical 
 
n=237 
15.30 
(3.00) 
5 to 20 
n=212 
15.20 
(2.93) 
5 to 20 
n=199 
14.95 
(3.14) 
6 to 20 
n=233 
15.37 
(2.90) 
7 to 20 
n=220 
15.07 
(2.86) 
6 to 20 
n=210 
14.78 
(2.97) 
6 to 20 
WHOQOL 
psychological 
n=237 
15.13 
(2.19) 
8 to 20 
n=212 
14.98 
(2.21) 
7 to 20 
n=199 
14.74 
(2.41) 
7 to 20 
n=233 
15.15 
(2.10) 
8 to 20 
n=220 
14.74 
(2.20) 
7 to 20 
n=210 
14.53 
(2.38) 
7 to 20 
WHOQOL social 
 
n=235 
15.19 
(2.67) 
5 to 20 
n=211 
15.03 
(2.47) 
7 to 20 
n=197 
15.04 
(2.72) 
8 to 20 
n=233 
15.07 
(2.66) 
7 to 20 
n=219 
14.80 
(2.58) 
7 to 20 
n=210 
14.51 
(2.83) 
5 to 20 
WHOQOL 
environmental 
n=237 
16.35 
(2.30) 
10 to 20 
n=212 
16.33 
(2.26) 
9 to 20 
n=199 
16.00 
(2.40) 
9 to 20 
n=233 
16.52 
(1.99) 
10 to 20 
n=220 
16.18 
(2.04) 
10 to 20 
n=210 
16.04 
(2.05) 
11 to 20 
EQ5D3L index 
 
n=235 
0.77 
(0.25) 
-0.18 to 1 
n=209 
0.75 
(0.24) 
-0.18 to 1 
n=196 
0.73 
(0.27) 
-0.18 to 1 
n=233 
0.79  
(0.24) 
-0.07 to 1 
n=217 
0.74 
(0.25) 
-0.24 to  1 
n=211 
0.75 
(0.23) 
-0.07 to 1 
EQ5D3L VAS 
 
n=234 
73.52 
(20.95) 
1 to 100 
n=208 
74.13 
(18.92) 
0 to 100 
n=198 
74.14 
(19.16) 
10 to 100 
n=233 
75.44 
(18.90) 
0 to 100 
n=217 
73.14 
(18.95) 
0 to 100 
n=211 
72.42 
(19.13) 
0 to 100 
Data are mean (s.d.) range. CR Cognitive rehabilitation, TAU Treatment as usual, RSS Relatives’ 
Stress Scale (higher scores indicate higher levels of caregiving-specific stress), WHOQOL-BREF 
World Health Organisation Quality of Life Instrument – brief version (higher scores indicate better 
quality of life), EQ5D3L European Quality of Life 5 Dimensions questionnaire Level version (higher 
score indicates higher health status), VAS Visual Analogue Scale (higher score indicates higher 
health status) 
 
(c) Statistical analyses at three-month follow up 
Measure p1 Bonferroni 
adjusted p 
Mean 
difference 
95% CI for 
mean 
difference 
d 95% CI for 
d 
PARTICIPANTS WITH 
DEMENTIA 
      
DEMQoL 0.738 1.000 0.24 -1.27 to 1.75 0.02 -0.16 to 0.20 
GSES 0.126 1.000 0.58 -0.16 to 1.32 0.11 -0.07 to 0.29 
HADS Depression 0.861 1.000 0.00 -0.42 to 0.41 0.02 -0.16 to 0.20 
HADS Anxiety 0.478 1.000 0.17 -0.30 to 0.65 0.06 -0.12 to 0.24 
RBMT immediate 
recall 
0.189 1.000 0.19 -0.10 to 0.48 0.10 -0.08 to 0.28 
RBMT delayed 
recall 
0.096 1.000 0.24 -0.04 to 0.52 0.12 -0.06 to 0.30 
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TEA elevator 
counting 
0.799 1.000 0.01 -0.19 to 0.21 0.02 -0.16 to 0.20 
TEA elevator 
counting with 
distraction 
0.784 1.000 0.01 -0.45 to 0.47 0.03 -0.15 to 0.21 
DKEFS verbal 
fluency 
0.794 1.000 0.15 -1.12 to 1.41 0.02 -0.16 to 0.20 
STUDY 
PARTNERS 
      
RSS 0.382 1.000 -0.50 -1.61 to 0.62 0.05 -0.13 to 0.23 
WHOQOL physical 0.431 1.000 0.12 -0.18 to 0.42 0.04 -0.14 to 0.22 
WHOQOL 
psychological 
0.214 1.000 0.18 -0.10 to 0.47 0.08 -0.10 to 0.26 
WHOQOL social 0.572 1.000 0.10 -0.25 to 0.45 0.05 -0.13 to 0.23 
WHOQOL 
environmental 
0.050 0.947 0.26 0 to 0.51 0.13 -0.06 to 0.31 
EQ5D3L index 0.295 1.000 0.02 -0.01 to 0.05 0.07 -0.11 to 0.25 
EQ5D Visual 
Analogue Scale 
0.286 1.000 1.58 -1.31 to 4.47 0.09 -0.09 to 0.27 
1
 19 adjustments in total to adjust for all the participant and carer outcome measure comparisons, 
except for the primary outcome. 
DEMQOL People with DEMentia Quality Of Life questionnaire (higher scores indicate better quality 
of life), GSES Generalized Self-Efficacy Scale (higher scores indicate stronger sense of perceived 
self-efficacy), HADS Hospital Anxiety and Depression Scale (higher scores indicate higher levels of 
anxiety and depression), RBMT Rivermead Behavioural Memory Test (higher scores indicate better 
performance), TEA Test of Everyday Attention (higher scores indicate better performance), D-KEFS 
Delis-Kaplan Executive Function System (higher scores indicate better performance). RSS Relatives’ 
Stress Scale (higher scores indicate higher levels of caregiving-specific stress), WHOQOL-BREF 
World Health Organisation Quality of Life Instrument – brief version (higher scores indicate better 
quality of life), EQ5D3L European Quality of Life 5 Dimensions questionnaire Level version (higher 
score indicates higher health status), VAS Visual Analogue Scale (higher score indicates higher 
health status). The d effect size estimates were based on a fixed effect size model as they cannot be 
derived directly from the mixed effects model, and were calculated by converting eta squared to r, and 
then converting r to d. 
 
 (d) Statistical analyses at nine month follow up 
Measure p2 Bonferroni 
adjusted p 
Mean 
difference 
95% CI for 
mean 
difference 
d 95% CI for d 
PARTICIPANTS WITH 
DEMENTIA 
      
DEMQOL 0.215 1.000 1.08 -0.62 to 2.78 0.09 -0.09 to 0.27 
GSES 0.38 1.000 0.37 -0.45 to 1.18 0.07 -0.11 to 0.25 
HADS Depression 0.614 1.000 0.12 -0.35 to 0.6 0.05 -0.13 to 0.23 
HADS Anxiety 0.334 1.000 0.26 -0.26 to 0.77 0.08 -0.1 to 0.26 
RBMT immediate 
recall 
0.496 1.000 0.10 -0.19 to 0.4 0.06 -0.12 to 0.24 
RBMT delayed 
recall 
0.466 1.000 -0.10 -0.37 to 0.17 0.06 -0.12 to 0.24 
TEA elevator 
counting 
0.718 1.000 -0.01 -0.27 to 0.25 0.04 -0.14 to 0.22 
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TEA elevator 
counting with 
distraction 
0.334 1.000 0.23 -0.23 to 0.69 0.09 -0.09 to 0.27 
DKEFS verbal 
fluency 
0.342 1.000 0.71 -0.75 to 2.16 0.06 -0.12 to 0.24 
STUDY 
PARTNERS 
      
RSS 0.808 1.000 0.08 -1.09 to 1.25 0.02 -0.16 to 0.2 
WHOQOL physical 0.399 1.000 0.14 -0.19 to 0.47 0.05 -0.13 to 0.23 
WHOQOL 
psychological 
0.346 1.000 0.15 -0.16 to 0.45 0.06 -0.12 to 0.24 
WHOQOL social 0.049 0.93 0.41 0 to 0.81 0.15 -0.03 to 0.33 
WHOQOL 
environmental 
0.371 1.000 0.13 -0.15 to 0.4 0.06 -0.12 to 0.24 
EQ5D3L index 0.547 1.000 -0.01 -0.04 to 0.02 0.04 -0.14 to 0.22 
EQ5D Visual 
Analogue Scale 
0.071 1.000 2.60 -0.22 to 5.42 0.14 -0.04 to 0.32 
2
 20 adjustments in total to adjust for all the participant and carer outcome measure comparisons. 
DEMQOL People with DEMentia Quality Of Life questionnaire (higher scores indicate better quality 
of life), GSES Generalized Self-Efficacy Scale (higher scores indicate stronger sense of perceived 
self-efficacy), HADS Hospital Anxiety and Depression Scale (higher scores indicate higher levels of 
anxiety and depression), RBMT Rivermead Behavioural Memory Test (higher scores indicate better 
performance), TEA Test of Everyday Attention (higher scores indicate better performance), D-KEFS 
Delis-Kaplan Executive Function System (higher scores indicate better performance). RSS Relatives’ 
Stress Scale (higher scores indicate higher levels of caregiving-specific stress), WHOQOL-BREF 
World Health Organisation Quality of Life Instrument – brief version (higher scores indicate better 
quality of life), EQ5D3L European Quality of Life 5 Dimensions questionnaire Level version (higher 
score indicates higher health status), VAS Visual Analogue Scale (higher score indicates higher 
health status). The d effect size estimates were based on a fixed effect size model as they cannot be 
derived directly from the mixed effects model, and were calculated by converting eta squared to r, and 
then converting r to d 
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Figure 1. Participant flow through the GREAT trial 
 
